Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $5.1 million.

  • Kyntra Bio's Current Deferred Revenue fell 8231.34% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 8231.34%. This contributed to the annual value of $27.3 million for FY2024, which is 11420.72% up from last year.
  • Per Kyntra Bio's latest filing, its Current Deferred Revenue stood at $5.1 million for Q3 2025, which was down 8231.34% from $27.3 million recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's Current Deferred Revenue registered a high of $28.9 million during Q3 2024, and its lowest value of $4.7 million during Q1 2022.
  • Over the past 5 years, Kyntra Bio's median Current Deferred Revenue value was $12.7 million (recorded in 2023), while the average stood at $15.0 million.
  • In the last 5 years, Kyntra Bio's Current Deferred Revenue soared by 29396.59% in 2024 and then tumbled by 8231.34% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Current Deferred Revenue stood at $15.9 million in 2021, then decreased by 19.66% to $12.7 million in 2022, then increased by 0.01% to $12.7 million in 2023, then skyrocketed by 114.21% to $27.3 million in 2024, then crashed by 81.3% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $27.3 million for Q2 2025, and $22.5 million during Q1 2025.